Worldwide Gene Therapy Industry to 2027 - Players Include Amgen, Biogen and Novartis Among Others

DUBLIN, March 4, 2022 /PRNewswire/ -- The "Gene Therapy Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027" report has been added to ResearchAndMarkets.com's offering.

The global gene therapy market reached a value of US$ 3.77 Billion in 2021. Looking forward, the publisher expects the market to reach a value of US$ 9.5 Billion by 2027 exhibiting a CAGR of 15.60% during 2022-2027. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic. These insights are included in the report as a major market contributor.

Gene therapy is a technique for preventing disease progression by modifying the expression of mutated genes or altering the biological properties of living cells for therapeutic use. It improves the ability of the body to fight against a wide range of diseases, such as cancer, diabetes, hemophilia, cystic fibrosis, heart disease, and acquired immunodeficiency syndrome (AIDS). Nowadays, a wide variety of gene therapy products are available worldwide, which include viral vectors, bacterial vectors, plasmid deoxyribonucleic acid (DNA), human gene-editing technology, and patient-derived cellular gene therapy.

Gene Therapy Market Trends:

The growing prevalence of inherited diseases and acquired disorders, in confluence with easy access to healthcare facilities, represents one of the key factors catalyzing the demand for gene therapy to improve the quality of life of patients. Moreover, the rising cases of genetic disorders, such as muscular dystrophy and cystic fibrosis, in children and young adults are bolstering the market growth. In line with this, the increasing geriatric population, which is more susceptible to develop infectious diseases on account of inappropriate gene activity, is contributing to the market growth.

Apart from this, the development of new gene therapy that offers a safer, non-addictive alternative to opioids in treating a broad range of chronic pain conditions, such as lower back pain and rare neuropathic pain disorders, is favoring the market growth. In addition, a large variety of therapeutic genes are under investigation, including tumor suppressor, anti-angiogenesis, inflammatory cytokine, and micro ribonucleic acid (RNA) genes. These genes can assist in treating cancer, leukemia, severe combined immune deficiency, and blindness caused by retinitis pigmentosa, which is anticipated to stimulate the growth of the market.

Key Market Segmentation:

The publisher provides an analysis of the key trends in each sub-segment of the global gene therapy market, along with forecasts at the global, regional and country level from 2022-2027. Our report has categorized the market based on gene type, vector type, delivery method and application.

Breakup by Gene Type:

• Antigen
• Cytokine
• Tumor Suppressor
• Suicide Gene
• Deficiency
• Growth Factors
• Receptors
• Others

Breakup by Vector Type:

• Viral Vector
• Adenoviruses
• Lentiviruses
• Retroviruses
• Adeno-Associated Virus
• Herpes Simplex Virus
• Poxvirus
• Vaccinia Virus
• Others
• Non-Viral Techniques
• Naked and Plasmid Vectors
• Gene Gun
• Electroporation
• Lipofection
• Others

Breakup by Delivery Method:

• In-Vivo Gene Therapy
• Ex-Vivo Gene Therapy

Breakup by Application:

• Oncological Disorders
• Rare Diseases
• Cardiovascular Diseases
• Neurological Disorders
• Infectious Disease
• Others

Breakup by Region:

• North America
• United States
• Canada
• Asia-Pacific
• China
• Japan
• India
• South Korea
• Australia
• Indonesia
• Others
• Europe
• Germany
• France
• United Kingdom
• Italy
• Spain
• Russia
• Others
• Latin America
• Brazil
• Mexico
• Others
• Middle East and Africa

Competitive Landscape:

The competitive landscape of the industry has also been examined along with the profiles of the key players being Abeona Therapeutics Inc., Adaptimmune Therapeutics plc, Adverum Biotechnologies Inc., Amgen Inc., Astellas Pharma Inc., Biogen Inc., Bluebird Bio Inc., Mustang Bio Inc. (Fortress Biotech Inc.), Novartis AG, Orchard Therapeutics plc, UniQure N.V. and Voyager Therapeutics Inc.

Key Questions Answered in this Report:

• How has the global gene therapy market performed so far and how will it perform in the coming years?
• What has been the impact of COVID-19 on the global gene therapy market?
• What are the key regional markets?
• What is the breakup of the market based on the gene type?
• What is the breakup of the market based on the vector type?
• What is the breakup of the market based on the delivery method?
• What is the breakup of the market based on the application?
• What are the various stages in the value chain of the industry?
• What are the key driving factors and challenges in the industry?
• What is the structure of the global gene therapy market and who are the key players?
• What is the degree of competition in the industry?

Key Topics Covered:

1 Preface

2 Scope and Methodology

3 Executive Summary

4 Introduction
4.1 Overview
4.2 Key Industry Trends

5 Global Gene Therapy Market
5.1 Market Overview
5.2 Market Performance
5.3 Impact of COVID-19
5.4 Market Forecast

6 Market Breakup by Gene Type
6.1 Antigen
6.1.1 Market Trends
6.1.2 Market Forecast
6.2 Cytokine
6.2.1 Market Trends
6.2.2 Market Forecast
6.3 Tumor Suppressor
6.3.1 Market Trends
6.3.2 Market Forecast
6.4 Suicide Gene
6.4.1 Market Trends
6.4.2 Market Forecast
6.5 Deficiency
6.5.1 Market Trends
6.5.2 Market Forecast
6.6 Growth Factors
6.6.1 Market Trends
6.6.2 Market Forecast
6.7 Receptors
6.7.1 Market Trends
6.7.2 Market Forecast
6.8 Others
6.8.1 Market Trends
6.8.2 Market Forecast

7 Market Breakup by Vector Type
7.1 Viral Vector
7.1.1 Market Trends
7.1.2 Key Segments
7.1.2.1 Adenoviruses
7.1.2.2 Lentiviruses
7.1.2.3 Retroviruses
7.1.2.4 Adeno-Associated Virus
7.1.2.5 Herpes Simplex Virus
7.1.2.6 Poxvirus
7.1.2.7 Vaccinia Virus
7.1.2.8 Others
7.1.3 Market Forecast
7.2 Non-Viral Techniques
7.2.1 Market Trends
7.2.2 Key Segments
7.2.2.1 Naked and Plasmid Vectors
7.2.2.2 Gene Gun
7.2.2.3 Electroporation
7.2.2.4 Lipofection
7.2.2.5 Others
7.2.3 Market Forecast

8 Market Breakup by Delivery Method
8.1 In-Vivo Gene Therapy
8.1.1 Market Trends
8.1.2 Market Forecast
8.2 Ex-Vivo Gene Therapy
8.2.1 Market Trends
8.2.2 Market Forecast

9 Market Breakup by Application
9.1 Oncological Disorders
9.1.1 Market Trends
9.1.2 Market Forecast
9.2 Rare Diseases
9.2.1 Market Trends
9.2.2 Market Forecast
9.3 Cardiovascular Diseases
9.3.1 Market Trends
9.3.2 Market Forecast
9.4 Neurological Disorders
9.4.1 Market Trends
9.4.2 Market Forecast
9.5 Infectious Disease
9.5.1 Market Trends
9.5.2 Market Forecast
9.6 Others
9.6.1 Market Trends
9.6.2 Market Forecast

10 Market Breakup by Region

11 SWOT Analysis

12 Value Chain Analysis

13 Porters Five Forces Analysis

14 Price Analysis

15 Competitive Landscape
15.1 Market Structure
15.2 Key Players
15.3 Profiles of Key Players
15.3.1 Abeona Therapeutics Inc.
15.3.1.1 Company Overview
15.3.1.2 Product Portfolio
15.3.2 Adaptimmune Therapeutics plc
15.3.2.1 Company Overview
15.3.2.2 Product Portfolio
15.3.3 Adverum Biotechnologies Inc.
15.3.3.1 Company Overview
15.3.3.2 Product Portfolio
15.3.3.3 Financials
15.3.4 Amgen Inc.
15.3.4.1 Company Overview
15.3.4.2 Product Portfolio
15.3.4.3 Financials
15.3.4.4 SWOT Analysis
15.3.5 Astellas Pharma Inc.
15.3.5.1 Company Overview
15.3.5.2 Product Portfolio
15.3.5.3 Financials
15.3.5.4 SWOT Analysis
15.3.6 Biogen Inc.
15.3.6.1 Company Overview
15.3.6.2 Product Portfolio
15.3.6.3 Financials
15.3.6.4 SWOT Analysis
15.3.7 Bluebird Bio Inc.
15.3.7.1 Company Overview
15.3.7.2 Product Portfolio
15.3.7.3 Financials
15.3.7.4 SWOT Analysis
15.3.8 Mustang Bio Inc. (Fortress Biotech Inc.)
15.3.8.1 Company Overview
15.3.8.2 Product Portfolio
15.3.9 Novartis AG
15.3.9.1 Company Overview
15.3.9.2 Product Portfolio
15.3.9.3 Financials
15.3.9.4 SWOT Analysis
15.3.10 Orchard Therapeutics plc
15.3.10.1 Company Overview
15.3.10.2 Product Portfolio
15.3.10.3 Financials
15.3.11 UniQure N.V.
15.3.11.1 Company Overview
15.3.11.2 Product Portfolio
15.3.11.3 Financials
15.3.12 Voyager Therapeutics Inc.
15.3.12.1 Company Overview
15.3.12.2 Product Portfolio
15.3.12.3 Financials

For more information about this report visit https://www.researchandmarkets.com/r/nl88si

Media Contact:

Research and Markets
Laura Wood, Senior Manager
[email protected]   

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1904
Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets